A study from the lab of @evnewell.bsky.social looks at the immune response to multiple myeloma. It turned out the most interesting thing was what they didn’t find: T cells that had already recognized and tried to fight off tumor cells. Read more: pubmed.ncbi.nlm.nih.gov/40163891/

Our collaborator @evnewell.bsky.social + others outline a new approach to identifying tumor-infiltrating #immune cells from spatial #transcriptomics. They explore cell segmentation methods . @nature.com @hutchinnovation.bsky.social #ImmuneSky www.nature.com/articles/s41...

Excited to share work from our team, released today. Check out how it compares to other methods on multiple platform's datasets. Would love to hear how it performs on your data. www.nature.com/articles/s41...

New independent single cell benchmarking study by the @fredhutch.bsky.social innovation lab. Check it out! www.biorxiv.org/content/10.1...

Phenotype and function of IL-10–producing NK cells in individuals with malaria experience @jci-insight.bsky.social insight.jci.org/articles/vie...

FHIL loves working with the Srivastava Lab! Their work explores factors enabling CAR-T response to checkpoint blockade in solid tumors. Infiltration of CAR-Ts was assessed spatially with a Xenium custom panel including probes targeting the construct and lung tumor. www.biorxiv.org/content/10.1...

Excited to share my graduate work from the @ejohnwherry.bsky.social lab on the molecular mechanisms locking in the differentiation fate of exhausted CD8 T cells (Tex), published earlier this month in @science.org immunology. Main findings below! www.science.org/doi/10.1126/...

Happy to share our new collaborative work! 🚨 We analyzed 2250 TCR repertoires to uncover how HLA risk alleles shape immune autoreactivity in T1D. T1D-specific HLA-motifs were also validated in pancreatic lymph nodes (pLN) & spleen. 🧬🧵 #T1D #Immunology #TCR 1/9

Sharing again for new followers - check out this fully-funded postdoc to work with any Fred Hutch comp bio faculty members! Pre-apps due Dec 20 to start next year! www.fredhutch.org/en/research/...

Please join us in welcoming Madhav Dhodapkar, MBBS, as the new leader of Fred Hutch’s #Myeloma Program. Dr. Dhodapkar, a board-certified hematologist and oncologist, is a renowned expert in the treatment of multiple myeloma and other hematologic malignancies. #ASH24 1/3

NiCo is out! Our new algorithm for spatial transcriptomics data analysis predicts the crosstalk of cell types co-localized in tissue niches and sheds light on signalling mediators and downstream effects of cell-cell interactions by inferring covarying gene programs. www.nature.com/articles/s41...